41. Referral for appropriate clinical management and genetic counselling must be recommended for all reportable variants identified during germline testing. 42. It must be clear from the report whether the result is from the analysis of tumour and/or germline tissue. 43. As a minimum, somatic test reports must recommend germline testing of the detected reportable variant if VAF is in the laboratory established germline range eg., > 30% (SNVs), > 20% (small indels) [44]. 44. The percentage neoplastic content must be stated on somatic test reports, and flagged if below the laboratory-determined acceptable threshold; as this is critical information for when a PV is not detected. 45. The report must clearly state whether analysis for CNVs/larger indels has been performed. 46. If CNV/larger indel analysis has not been completed on the tumour sample, then germline CNV/larger indel testing for BRCA1/2 should be recommended (unless HRD is not detected on an assay for which response to PARPi has been demonstrated in clinical trials, or on one that is benchmarked to such an assay [HRD negative]), and the limitations of somatic-only testing clearly stated. 47. If germline testing has not identified a reportable variant, then somatic testing should be recommended, and the limitations of germline-only testing clearly stated. 48. As applicable, reports should refer to PARPi therapy rather than brand names